Sugi Predict

Sugi Predict / Compounds / SCHEMBL2923341

SCHEMBL2923341

SCHEMBL2923341

CCOC(=O)c1c(-c2cccc(C)c2)noc1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ LMNA P02545 3/20 0.62
▸ HPGD P15428 2/20 0.62
▸ PTBP1 P26599 2/20 0.62
▸ CYP3A4 P08684 2/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ GPBAR1 Q8TDU6 1/20 0.58
▸ POLB P06746 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ ATM Q13315 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.52
▸ NPC1 O15118 1/20 0.51
▸ CACNA1F O60840 1/20 0.50
▸ ABCB1 P08183 1/20 0.50
▸ CACNA1D Q01668 1/20 0.50
▸ CACNA1S Q13698 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776068 0.87 GPBAR1 (0.59) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL2779302 0.87 TDP1 (0.66) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL536297 0.86 TSHR (0.74) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL13615398 0.86 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL2776267 0.84 TSHR (0.70) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL2923610 0.83 ATM (0.64) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL20501792 0.83 MEN1 (0.61) SMN1; SMN2ALDH1A1LMNAL3MBTL1TDP1
SCHEMBL2777083 0.83 TDP1 (0.53) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL4333884 0.82 GPBAR1 (0.60) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1
SCHEMBL2930011 0.81 POLB (0.63) SMN1; SMN2ALDH1A1LMNAHPGDPTBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 — — EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 — — US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 — — EP disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 — — US disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 — — EP disclosed
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-24 — — US disclosed
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-8518974-B2 Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (US) 2013-08-27 — — US disclosed
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-07-19 — — US disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 — — EP disclosed
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 — — US disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 — — WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 — — US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 — — US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 — — US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 — — US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 SMN1; SMN2 3318/4885ALDH1A1 938/4885LMNA 3918/4885
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 SMN1; SMN2 3354/4885ALDH1A1 955/4885LMNA 3905/4885
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BACE1, APP, BACE2 SMN1; SMN2 630/4885ALDH1A1 2144/4885LMNA 961/4885
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 SMN1; SMN2 3354/4885ALDH1A1 955/4885LMNA 3905/4885
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 SMN1; SMN2 3354/4885ALDH1A1 955/4885LMNA 3905/4885
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 SMN1; SMN2 3354/4885ALDH1A1 955/4885LMNA 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.